Share 'Conference Call 48-Week Results From the Phase IIb exon 51 skip DMD Study'
Sarepta Therapeutics Announces Conference Call and Webcast on Wednesday, October 3, 2012, to Discuss 48-Week Results From the Phase IIb DMD Study Oct 02, 2012 (Marketwire via COMTEX) --Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Wednesday, October 3, 2012 to discus…
You can share this discussion in two ways…
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
